Results 51 to 60 of about 1,772,527 (156)

Epigenetic Predictors of Smoking: External Validation and Association With Smoking‐Related Cancer Risk

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Tobacco smoking has a strong influence on DNA methylation (DNAm), enabling the development of DNAm‐based smoking predictors, yet external evaluations of these have remained limited. We aimed to assess six DNAm‐based smoking predictors in a large sample of middle‐aged and older Australians for (i) their accuracy and reliability, and (ii) their ...
Xiaoyu Fan   +8 more
wiley   +1 more source

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia

open access: yesClinical Case Reports, 2023
Key Clinical Message Hypomethylating agents may be useful in some but not all cases of myelodysplastic syndromes. In some versions of these conditions, this treatment may yield deleterious results.
Anwarul Islam
doaj   +1 more source

Supplementary Methods and Figure Legends 1-2 from RETRACTED: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation

open access: yes, 2009
Supplementary Methods and Figure Legends 1-2 from RETRACTED: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its ...
Sanjeev Redkar (7924052)   +7 more
core   +1 more source

Early Chidamide Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in High‐Risk Myeloid Malignancies: A Prospective Cohort With Time‐Dependent External‐Control Analysis

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Chidamide is an oral histone deacetylase inhibitor whose use as early maintenance after allogeneic hematopoietic stem cell transplantation (HSCT) remains insufficiently defined. This prospective single‐center Phase 1/2 cohort included all 47 patients enrolled and treated by March 31, 2026.
Haonan Yang   +9 more
wiley   +1 more source

Supplementary Figures 1-2 from RETRACTED: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation

open access: yes, 2009
Supplementary Figures 1-2 from RETRACTED: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its ...
Sanjeev Redkar (7924052)   +7 more
core   +1 more source

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents [PDF]

open access: yes, 2020
Acute myeloid leukemia (AML) is driven by leukemia stem cells (LSCs) that resist conventional chemotherapy and are the major cause of relapse$^{1,2}$. Hypomethylating agents (HMAs) are the standard of care in the treatment of older or unfit patients with
de Haard, Hans   +66 more
core   +3 more sources

Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials

open access: yesiNew Medicine, EarlyView.
ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong   +5 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre   +5 more
wiley   +1 more source

The euphoria of hypomethylating agents in MDS and AML: Is it justified?

open access: yes, 2013
While it is logical to use hypomethylating agents to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), trial results with azacitidine and decitabine have been inconsistent.
Sekeres, Mikkael A.
core   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy